Phase 2
N=147
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain
Osteoarthritis
Bottom Line
View on ClinicalTrials.gov: NCT05620563 ↗Enrolled (actual)
147
Serious AEs
0.7%
Results posted
Jun 2024
Primary outcome: Primary: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.13; -1.43 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- LY3857210 (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- Eli Lilly and Company
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) |
-1.13; -1.43 | — |
| SECONDARY Change From Baseline on the Western Ontario and McMaster University Arthritis Index (WOMAC®) Pain Subscale |
-2.44; -2.29 | — |
| SECONDARY Change From Baseline on the WOMAC® Stiffness Subscale |
-1.32; -0.85 | — |
| SECONDARY Change From Baseline on the WOMAC® Physical Function Subscale |
-8.62; -8.07 | — |
| SECONDARY Change From Baseline in Overall Improvement as Measured by Patient's Global Impression of Change |
3.07; 2.99 | — |
| SECONDARY Change From Baseline for Worst Pain Intensity as Measured by NRS |
-1.25; -1.54 | — |
| SECONDARY Change From Baseline on the Visual Analog Scale (VAS) for Pain |
-16.02; -18.21 | — |
| SECONDARY Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep |
-0.03; 0.05 | — |
| SECONDARY Total Amount of Rescue Medication Use as Measured by Average Daily Dosage |
198.16; 174.01 | — |
| SECONDARY Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm) |
0.05; 0.06 | — |
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3857210 in participants with Osteoarthritic Pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Eligibility Criteria
Inclusion Criteria
- Have a visual analog scale (VAS) pain value ≥40 and 12 weeks at screening.
- Have an x-ray supporting diagnosis of osteoarthritis according to the American College of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of index knee.
- Are men, or women able to abide by reproductive and contraceptive requirements.
Exclusion Criteria
- A seizure disorder, history of seizure (other than remote history of childhood febrile seizure), or a condition that would place the participant at increased risk of seizure
- Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques).
- Have surgery planned during the study for any reason, related or not to the disease state under evaluation.
- Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
- Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
- Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association).
- Have a positive human immunodeficiency virus (HIV) test result at screening.
- Are in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
- Have an intolerance to acetaminophen or paracetamol or any of its excipients.
- Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.
- Are largely or wholly incapacitated and unable to participate fully in all protocol procedures, for example, bedridden or confined to a wheelchair, permitting little or no selfcare.
- Have presence of surgical hardware or other foreign body in the index knee.
- Have an unstable index joint (such as a torn anterior cruciate ligament).
- Have had a surgical procedure or therapeutic injection in the affected knee within 3 months prior to starting the washout period.
- Have fibromyalgia, chronic pain syndrome, or other concurrent medical or arthritic conditions that could interfere with the evaluation of the index knee.
- Have a history of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis.
- Have clinical signs and symptoms of active knee infection or crystal disease of the index knee.
- Have a history of infection in the index joint.
- Have a history of arthritis due to crystals (e.g., gout, pseudogout).
- Have pain or functional impairment due to ipsilateral hip osteoarthritis.
- Have had any joint replacement such as knee of the lower extremity, such as hip, knee or ankle, in the past 6 months.
- Are pregnant or breastfeeding.
Data sourced from ClinicalTrials.gov (NCT05620563). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.